PT1796660T - Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta - Google Patents

Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta

Info

Publication number: PT1796660T
Authority: PT; Portugal
Prior art keywords: 1beta; inhibition; dioxyethylene; tellurate; interleukin
Prior art date: 2004-09-17

Application number

PT57796393T

Other languages

English (en)

Inventor

Albeck Michael

Sredni Benjamin

Original Assignee

Biomas Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-17

Filing date

2005-09-15

Publication date

2017-02-13

2005-09-15 Application filed by Biomas Ltd filed Critical Biomas Ltd

2017-02-13 Publication of PT1796660T publication Critical patent/PT1796660T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C395/00—Compounds containing tellurium
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)

PT57796393T 2004-09-17 2005-09-15 Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta PT1796660T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US61066004P	2004-09-17	2004-09-17

Publications (1)

Publication Number	Publication Date
PT1796660T true PT1796660T (pt)	2017-02-13

Family

ID=35985262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT57796393T PT1796660T (pt)	2004-09-17	2005-09-15	Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta

Country Status (10)

Country	Link
US (5)	US20090269418A1 (pt)
EP (3)	EP1796660B1 (pt)
JP (1)	JP2008513439A (pt)
AT (1)	ATE402709T1 (pt)
AU (1)	AU2005283719A1 (pt)
CA (3)	CA2580804A1 (pt)
DE (1)	DE602005008622D1 (pt)
ES (2)	ES2312012T3 (pt)
PT (1)	PT1796660T (pt)
WO (3)	WO2006030437A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1694313A4 (en)	2003-12-18	2010-11-17	Biomas Ltd	TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES
JP4903057B2 (ja) *	2004-01-22	2012-03-21	バイオマスリミテッド	いぼをテルル化合物により治療するための治療法および医薬組成物
EP1796660B1 (en) *	2004-09-17	2016-11-23	BioMAS Ltd.	Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
US20080260770A1 (en) *	2004-09-17	2008-10-23	Biomas Ltd.	Use of Tellurium Compounds as Adjuvants
EP1841597A4 (en)	2005-01-11	2010-01-27	Jemtex Ink Jet Printing Ltd	INK JET PRINTER AND CONTROL METHOD THEREFOR
AU2006290297A1 (en) *	2005-09-15	2007-03-22	Biomas Ltd.	Use of tellurium compounds for protection from ultra-violet radiation
ATE457729T1 (de) *	2006-06-01	2010-03-15	Nobera Pharma Sl	Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
EP1862166A1 (en) *	2006-06-01	2007-12-05	Yolanda Rodemer	Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
JP2010502764A (ja)	2006-09-11	2010-01-28	バイオマスリミテッド	テルル含有化合物の局所製剤
WO2009066300A2 (en) *	2007-11-23	2009-05-28	Biomas Ltd.	Methods and compositions for inhibiting integrins using tellurium-containing compounds
WO2009066301A2 (en) *	2007-11-23	2009-05-28	Biomas Ltd.	Methods and compositions for treating pox virus with tellurium-containing compounds
US20120035260A1 (en) *	2009-01-08	2012-02-09	Biomas Ltd.	Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy
WO2010079488A1 (en) *	2009-01-08	2010-07-15	Biomas Ltd.	Tellurium-containing compounds for affecting male's fertility following chemotherapy and/or radiotherapy
EP2246057A1 (en)	2009-04-29	2010-11-03	Nobera Pharma, S.L.	Use of allopurinol for the treatment of hand foot skin reaction
WO2010146547A1 (en) *	2009-06-16	2010-12-23	Biomas Ltd.	Tellurium-containing compounds for facilitating transplantation
JP2013506687A (ja)	2009-09-30	2013-02-28	プレジデントアンドフェロウズオブハーバードカレッジ	オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
WO2012065065A1 (en) *	2010-11-12	2012-05-18	Follica, Inc.	Methods and compositions for modulating hair growth, wound healing and scar revision
WO2012078649A1 (en)	2010-12-06	2012-06-14	Follica, Inc.	Methods for treating baldness and promoting hair growth
US11596652B2 (en)	2015-02-18	2023-03-07	Enlivex Therapeutics R&D Ltd	Early apoptotic cells for use in treating sepsis
US11000548B2 (en)	2015-02-18	2021-05-11	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en)	2015-02-18	2022-05-03	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en)	2015-02-18	2022-04-19	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en)	2015-02-18	2022-11-15	Enlivex Therapeutics R&D Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en)	2015-02-18	2023-05-03	Enlivex Therapeutics Rdo Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en)	2015-04-21	2021-07-01	Enlivex Therapeutics Rdo Ltd	Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11730761B2 (en)	2016-02-18	2023-08-22	Enlivex Therapeutics Rdo Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
CN110494419B (zh) *	2017-04-28	2022-03-01	国立大学法人京都大学	有机碲化合物及其制造方法、活性自由基聚合引发剂、乙烯基聚合物的制造方法和乙烯基聚合物
IL321754A (en)	2017-06-30	2025-08-01	Univ California	Compositions and methods for modulating hair growth
MX2020002389A (es) *	2017-09-29	2020-10-01	Univ California	Composiciones y metodos para modular el crecimiento del cabello.
JP2021042161A (ja) *	2019-09-11	2021-03-18	国立大学法人東海国立大学機構	脱毛剤、脱毛モデル動物及び白髪モデル動物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3369550A (en) *	1967-02-17	1968-02-20	Thomas A. Armao	Cryogenic clamps
GB1427415A (en)	1973-09-21	1976-03-10	Armao T A	Cryosurgical instruments
US4139619A (en) *	1976-05-24	1979-02-13	The Upjohn Company	6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4962207A (en)	1985-09-30	1990-10-09	Bar-Ilan University	Organic derivatives of tellurium and selenium
US5102908A (en) *	1985-03-15	1992-04-07	Michael Albeck	Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4761490A (en)	1985-03-15	1988-08-02	Bar-Ilan University	Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US5093135A (en) *	1985-09-30	1992-03-03	Michael Albeck	Compounds for the induction of in vivo and in vitro production of cytokines
US4752614A (en) *	1985-09-30	1988-06-21	Bar-Ilan University	Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4764461A (en) *	1985-09-30	1988-08-16	Bar-Ilan University	Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) *	1988-03-24	1990-05-29	Bar-Ilan University	Complexes of tellurium and selenium derivatives
DE4007473A1 (de)	1990-03-09	1991-09-12	Tomsk G Med I	Kryoskalpell
US5271925A (en) *	1990-03-09	1993-12-21	Benjamin Sredni	Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
US5213899A (en) *	1990-12-17	1993-05-25	General Electric Company	Room temperature vulcanizable silicone compositions
US5262149A (en)	1992-08-13	1993-11-16	Benjamin Sredni	Method of treating or preventing alopecia
RU2152789C2 (ru)	1994-09-01	2000-07-20	Фармация Энд Апджон Компани	Стерильная водная фармацевтическая композиция на основе лазароида или его фармацевтически приемлемой соли для парентерального введения
US5576347A (en) *	1994-11-14	1996-11-19	Sredni; Benjamin	Method of treating gastric ulcers
US5654328A (en)	1994-12-15	1997-08-05	Sredni; Benjamin	Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
EP0793499B1 (en)	1994-12-15	2005-10-19	Baker Norton Pharmaceuticals, Inc.	Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
EP2261232A3 (en) *	1998-03-19	2011-04-20	Vertex Pharmaceuticals Incorporated	Inhibitors of caspases
US6428534B1 (en)	1999-02-24	2002-08-06	Cryovascular Systems, Inc.	Cryogenic angioplasty catheter
DE60035037T2 (de) *	1999-04-09	2008-01-31	Cytovia, Inc., San Diego	Caspase inhibitoren und ihre verwendung
AP2002002407A0 (en) *	2000-05-23	2002-03-31	Vertex Pharma	Caspase inhibitors and uses thereof.
AU7527901A (en) *	2000-06-07	2001-12-17	Vertex Pharma	Caspase inhibitors and uses thereof
AU2001218024A1 (en)	2000-06-19	2002-01-02	University Of Southern California	Methods for treating and preventing alopecia
US6747008B1 (en)	2000-06-19	2004-06-08	University Of Southern California	Methods for treating and preventing alopecia
AU2002232541A1 (en) *	2000-11-21	2002-06-03	Vertex Pharmaceuticals Incorporated	Imidazole and benzimidazole caspase inhibitors and uses thereof
US20030148970A1 (en) *	2001-01-12	2003-08-07	Besterman Jeffrey M.	Methods for specifically inhibiting histone deacetylase-4
US7351702B2 (en) *	2001-05-23	2008-04-01	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
US6472381B1 (en)	2001-10-12	2002-10-29	Biomas Inc.	Method of treating psoriasis
IL146694A (en)	2001-11-22	2010-12-30	Biomas Ltd	Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
IL165986A0 (en) *	2002-06-28	2006-01-15	Vertex Pharma	Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same
EP1581501A1 (en) *	2002-12-20	2005-10-05	Vertex Pharmaceuticals Incorporated	4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
EP1694313A4 (en) *	2003-12-18	2010-11-17	Biomas Ltd	TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES
CA2580399C (en)	2004-09-15	2015-07-07	Itamar Medical Ltd.	Method and apparatus for non-invasively measuring physiological parameters, particularly blood flow and venous capacitance
EP1796660B1 (en)	2004-09-17	2016-11-23	BioMAS Ltd.	Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
US20080260770A1 (en) *	2004-09-17	2008-10-23	Biomas Ltd.	Use of Tellurium Compounds as Adjuvants

2005
- 2005-09-15 EP EP05779639.3A patent/EP1796660B1/en not_active Expired - Lifetime
- 2005-09-15 CA CA002580804A patent/CA2580804A1/en not_active Abandoned
- 2005-09-15 CA CA2580643A patent/CA2580643C/en not_active Expired - Fee Related
- 2005-09-15 ES ES05779419T patent/ES2312012T3/es not_active Expired - Lifetime
- 2005-09-15 EP EP05784166A patent/EP1802292A4/en not_active Withdrawn
- 2005-09-15 AU AU2005283719A patent/AU2005283719A1/en not_active Abandoned
- 2005-09-15 CA CA2580642A patent/CA2580642C/en not_active Expired - Fee Related
- 2005-09-15 ES ES05779639.3T patent/ES2614113T3/es not_active Expired - Lifetime
- 2005-09-15 DE DE602005008622T patent/DE602005008622D1/de not_active Expired - Lifetime
- 2005-09-15 WO PCT/IL2005/000989 patent/WO2006030437A2/en not_active Ceased
- 2005-09-15 WO PCT/IL2005/000991 patent/WO2006030439A2/en not_active Ceased
- 2005-09-15 US US11/662,743 patent/US20090269418A1/en not_active Abandoned
- 2005-09-15 AT AT05779419T patent/ATE402709T1/de not_active IP Right Cessation
- 2005-09-15 PT PT57796393T patent/PT1796660T/pt unknown
- 2005-09-15 EP EP05779419A patent/EP1791535B1/en not_active Expired - Lifetime
- 2005-09-15 JP JP2007531953A patent/JP2008513439A/ja active Pending
- 2005-09-15 WO PCT/IL2005/000990 patent/WO2006030438A2/en not_active Ceased
- 2005-09-15 US US11/663,032 patent/US7709524B2/en not_active Expired - Fee Related
- 2005-09-15 US US11/663,031 patent/US7652065B2/en not_active Expired - Fee Related
2009
- 2009-12-02 US US12/629,071 patent/US20100081623A1/en not_active Abandoned
2010
- 2010-03-22 US US12/728,362 patent/US8623908B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2005283719A1 (en)	2006-03-23
EP1802292A2 (en)	2007-07-04
JP2008513439A (ja)	2008-05-01
US20100233294A1 (en)	2010-09-16
ES2312012T3 (es)	2009-02-16
EP1796660B1 (en)	2016-11-23
US20090269418A1 (en)	2009-10-29
US8623908B2 (en)	2014-01-07
US20070298124A1 (en)	2007-12-27
EP1796660A4 (en)	2008-01-16
WO2006030437A3 (en)	2006-06-22
US20080015175A1 (en)	2008-01-17
ATE402709T1 (de)	2008-08-15
WO2006030438A2 (en)	2006-03-23
CA2580643A1 (en)	2006-03-23
HK1103355A1 (en)	2007-12-21
EP1802292A4 (en)	2008-02-13
WO2006030437A2 (en)	2006-03-23
WO2006030439A2 (en)	2006-03-23
EP1791535A2 (en)	2007-06-06
WO2006030439A3 (en)	2007-05-18
US7652065B2 (en)	2010-01-26
WO2006030438A3 (en)	2006-05-04
CA2580643C (en)	2018-06-12
CA2580642A1 (en)	2006-03-23
US20100081623A1 (en)	2010-04-01
DE602005008622D1 (de)	2008-09-11
ES2614113T3 (es)	2017-05-29
EP1796660A2 (en)	2007-06-20
EP1791535B1 (en)	2008-07-30
CA2580804A1 (en)	2006-03-23
US7709524B2 (en)	2010-05-04
CA2580642C (en)	2014-09-02

Publication	Publication Date	Title
PT1796660T (pt)	2017-02-13	Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
SG164368A1 (en)	2010-09-29	Treatment of cancer
SI1940786T1 (sl)	2010-11-30	Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
TW200519202A (en)	2005-06-16	Modulation of eIF4E expression
MY163477A (en)	2017-09-15	Pyrimidinyl-pyridazinone derivatives
TW200502385A (en)	2005-01-16	Modulation of forkhead box o1a expression
WO2003080566A3 (en)	2003-12-11	Hif hydroxylase inhibitors
SG132683A1 (en)	2007-06-28	Imidazopyrazine tyrosine kinase inhibitors
SG151327A1 (en)	2009-04-30	Deazapurines useful as inhibitors of janus kinases
EA201000563A1 (ru)	2010-10-29	Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
EP1876893A4 (en)	2010-09-01	TREATMENT OF CANCER BY THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
NO20063572L (no)	2003-02-24	Kinazolinditosylatsalt forbindelser
TW200510334A (en)	2005-03-16	Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
TW200720268A (en)	2007-06-01	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2006078287A3 (en)	2007-03-29	Pde4b inhibitors and uses therefor
WO2006042249A3 (en)	2007-03-01	Methods and compositions for treating migraine pain
TW200608979A (en)	2006-03-16	Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2008009579A (es)	2008-09-25	Metodo para el tratamiento de dolor neuropatico.
ZA200802848B (en)	2009-01-28	Potassium channel inhibitors
NO20093542L (no)	2010-02-12	Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
TW200736229A (en)	2007-10-01	Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
ATE549024T1 (de)	2012-03-15	Chinazolin-kaliumkanalhemmer
MY151937A (en)	2014-07-31	Water treatment composition
WO2005014607A3 (en)	2006-06-08	Antisense modulation of stearoyl-coa desaturase expression